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Abstract
Background: We previously demonstrated that nuclear and cytoplasmic accumulation of the intracellular domain (Ep-ICD)
of epithelial cell adhesion molecule (EpCAM) accompanied by a reciprocal reduction of its extracellular domain (EpEx),
occurs in aggressive thyroid cancers. This study was designed to determine whether similar accumulation of Ep-ICD is a
common event in other epithelial cancers.
Methodology and Results: Ten epithelial cancers were immunohistochemically analyzed using Ep-ICD and EpEx domain-
specific antibodies. The subcellular localization of EpEx and Ep-ICD in the human colon adenocarcinoma cell line CX-1 was
observed using immunofluorescence. Nuclear and cytoplasmic Ep-ICD expression was increased in cancers of the breast (31
of 38 tissues, 82%), prostate (40 of 49 tissues, 82%), head and neck (37 of 57 tissues, 65%) and esophagus (17 of 46 tissues,
37%) compared to their corresponding normal tissues that showed membrane localization of the protein. Importantly, Ep-
ICD was not detected in the nuclei of epithelial cells in most normal tissues. High nuclear and cytoplasmic Ep-ICD
accumulation also occurred in the other six epithelial cancer types analyzed - lung, colon, liver, bladder, pancreatic, and
ovarian. A concomitant reduction in membrane EpEx expression was observed in a subset of all cancer types. Receiver
operating characteristic curve analysis revealed nuclear Ep-ICD distinguished breast cancers with 82% sensitivity and 100%
specificity and prostate cancers with 82% sensitivity and 78% specificity. Similar findings were observed for cytoplasmic
accumulation of Ep-ICD in these cancers. We provide clinical evidence of increased nuclear and cytoplasmic Ep-ICD
accumulation and a reduction in membranous EpEx in these cancers.
Conclusions: Increased nuclear and cytoplasmic Ep-ICD was observed in all epithelial cancers analyzed and distinguished
them from normal tissues with high-sensitivity, specificity, and AUC. Development of a robust high throughput assay for Ep-
ICD will facilitate the determination of its diagnostic, prognostic and therapeutic relevance in epithelial cancers.
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Introduction
Epithelial cell adhesion molecule (EpCAM) is a 40 kDa
transmembrane glycoprotein that serves important roles in cell
adhesion, cell proliferation, differentiation, migration, cell cycle
regulation and is implicated in cancer and stem cell signalling [1].
EpCAM is one of the most widely investigated proteins in human
cancers, frequently overexpressed in human malignancies, local-
ized on the plasma membrane of tumor cells and albeit at lower
levels in the normal epithelia [2,3,4,5,6,7,8,9,10,11,12,13,14,15,
16,17]. All these studies used antibodies directed against the
extracellular domain of EpCAM (EpEx) [13]. These numerous
reports on the cell surface expression of EpCAM in human cancers
have suggested that it could be an ideal candidate for application
as an epithelial cancer marker and a therapeutic target
[18,19,20,21]. Paradoxically, most clinical trials using murine
monoclonal antibodies namely, edrecolomab in colorectal cancer,
or the humanized antibody, adecatumumab, in breast cancer have
shown limited efficacy [14,22]. An understanding of these
limitations poses a challenge for oncologists and is of great
importance for future development of more effective anti-EpCAM
strategies. In this context, Gires and Baeuerle [23] discussed the
need to measure EpCAM expression levels in tumor cells and their
impact on the outcome of a clinical trial. However, none of the
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prospectively or retrospectively. Whether the recently reported
regulated intramembrane proteolysis (RIP) mediated loss of
EpCAM from the tumor cell surface might be one of the reasons
for the limited efficacy of EpCAM-based cancer therapies remains
to be established [24]. The cleavage of the EpCAM ectodomain,
EpEx, by the protease tumor necrosis factor a converting enzyme
(TACE) and its shedding has been shown to release its intracellular
domain (Ep-ICD) which then translocates to the nucleus resulting
in activation of oncogenic signalling [24]. The association of Ep-
ICD with FHL2 and Wnt pathway components b-catenin and
Lef-1 forms a nuclear complex that binds DNA at Lef-1 consensus
sites and induces gene transcription, leading to increased cell
proliferation [24]. The clinical significance of Ep-ICD in human
cancers needs to be determined in view of the multiple roles of
EpCAM as an oncogenic signal transducer, cell adhesion molecule
and cancer stem cell marker [24,25,26,27].
Nuclear localization of Ep-ICD was first reported in a study of
26 cases of human colon cancer, but not in normal colonic
epithelia [24]. Subsequently, we reported nuclear and cytoplasmic
accumulation of Ep-ICD in different subtypes of thyroid cancers
that was associated with a reciprocal reduction in membranous
EpEx, and also observed a correlation of nuclear Ep-ICD
accumulation with tumor aggressiveness and poor disease
prognosis [28]. The wide heterogeneity in solid tumors warrants
investigation to determine whether nuclear and cytoplasmic Ep-
ICD expression may also occur in other human cancers. In the
current study, the subcellular compartmental accumulation of Ep-
ICD has been addressed in a wide variety of epithelial cancers,
namely, breast, prostate, head and neck, esophagus, ovary,
pancreas, colon and rectum, lung, urinary bladder, liver
carcinomas by immunohistochemistry (IHC) (using a specific
antibody directed against the Ep-ICD domain of EpCAM).
Nuclear and cytoplasmic Ep-ICD has also been quantitatively
detected in CX-1 colon cancer cells using immunofluorescence.
With the exception of a previous report in colon cancer and our
study in thyroid cancer [24,28], the novelty of this report is the
demonstration of the widespread occurrence of increased nuclear
and cytoplasmic accumulation of Ep-ICD in association with
variable membrane EpEx expression in a wide spectrum of
epithelial cancers.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by Mount
Sinai Hospital Research Ethics Board, Toronto, Canada. The
archived paraffin tissue blocks of a head and neck cancer study
approved by the Human Ethics Committee of All India Institute of
Medical Sciences, New Delhi, India, with prior consent of the
patients, were used in this study.
Patients and tissue specimens
For IHC analysis, archived tissue blocks of head and neck
squamous cell carcinomas (HNSCCs) and normal tissues as well as
esophageal squamous cell carcinomas (ESCCs) were retrieved
from the tumor bank, reviewed by the pathologist and used for
cutting tissue sections for immunostaining with Ep-ICD and EpEx
antibodies as described below. The clinical and pathological data
recorded included clinical tumor stage, site of the lesions,
histopathological differentiation, age and gender in a pre-designed
performa as described by us previously [29]. Tissue-microarrays
(TMA) of breast cancer and adjacent normal breast tissue (IMH-
371), prostate cancer and adjacent normal prostate tissue (IMH-
303), lung cancer (IMT-305), colon and rectal cancer (IMH-306),
common epithelial cancers comprising of liver, urinary bladder,
ovaries, pancreas, breast and prostate (IMH-327) were procured
from Imgenex Corp (San Diego, CA). Twenty-one tissue blocks of
benign prostate hyperplasia (BPH) were retrieved from the tissue
bank in Mount Sinai Hospital, reviewed by the pathologist and
used for cutting tissue sections for immunostaining with Ep-ICD
and EpEx antibodies.
Antibodies and Cell Line
Anti-human Ep-ICD rabbit monoclonal antibody was obtained
from Epitomics Inc. (Burlingame, CA). Anti-human EpEx mouse
monoclonal antibody (MOC-31) was obtained from AbD serotec
(Raleigh, NC). The a-Ep-ICD antibody 1144 recognizes the
cytoplasmic domain of human EpCAM and has been used in our
recent study on Ep-ICD in thyroid cancer [28]. MOC-31
recognizes the extracellular domain of EpCAM. Both antibodies
have been used in our recent study in thyroid cancer [28].
The human colon adenocarcinoma cell line CX-1 was cultured
in RPMI-1640 media containing 100 mg/mL streptomycin and
100 U/mL penicillin, 10% fetal bovine serum (FBS) and 1% non-
essential amino acids. The STR profile of the cell line was found to
be in accordance with the known profile of CX-1 in the databases
of the German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany).
Clinicopathological characteristics of patients
Fifty-seven HNSCC patients, ranging in age from 29 to 75 years
were enrolled in this study. Their diagnoses were based on clinical
examination and histopathological analysis of the tissue specimens.
The tumors were histologically graded as well differentiated
squamous cell carcinoma (WDSCC), moderately differentiated
squamous cell carcinoma (MDSCC) or poorly differentiated
squamous cell carcinoma (PDSCC). Twenty tissues taken from a
distant site of HNSCCs (with histologically confirmed normal
epithelia referred to here as head and neck normal tissues) were
also evaluated for Ep-ICD and EpEx expression.
Forty-six ESCC patients were enrolled in this study. Their
diagnoses were based on clinical examination and histopatholog-
ical analysis of the tissue specimens. The tumors were histolog-
ically graded as well, moderately or poorly differentiated SCCs.
Twenty tissues taken from a distant site of ESCCs (with
histologically confirmed normal epithelia referred to here as
esophageal normal tissues) were also evaluated for Ep-ICD protein
expression. Similarly, forty tissues taken from a distant site of
ESCCs (with histologically confirmed normal epithelia referred to
here as esophageal normal tissues) were evaluated for EpEx
expression.
TMAs of breast cancer and adjacent normal breast tissue,
prostate cancer and adjacent normal prostate tissue, lung cancer,
colon and rectal cancer, common epithelial cancers comprising of
liver, urinary bladder, ovaries, pancreas, breast and prostate were
examined. For Ep-ICD, the number of tissues analyzed were 38
breast cancers and 25 corresponding normal tissues, 49 prostate
cancers and 9 corresponding normal tissues and 21 benign
prostate hyperplasias, 57 HNSCCs and 20 corresponding normal
tissues, 46 ESCCs and 20 corresponding normal tissues, 59 each of
lung and colon cancers, 10 each of bladder, ovarian and
pancreatic cancers, and 9 liver cancers. For EpEx, the number
of tissues that were available for immunohistochemical analysis
included 40 breast cancers and 29 corresponding normal tissues,
49 prostate cancers and 9 corresponding normal tissues and 21
benign prostate hyperplasias, 39 HNSCCs and 20 corresponding
Ep-ICD in Epithelial Cancers
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cases each of lung and colon cancers, and 10 cases each of bladder,
ovarian, and liver cancers.
Immunohistochemical analysis of Ep-ICD expression in
epithelial cancers
Serial paraffin-embedded sections (5 mm thickness) of HNSCCs,
ESCCs and their normal tissues were used for Ep-ICD and EpEx
immunostaining as we have described recently [28]. The TMA slides
and the individual tissue sections were de-paraffinized by baking at
62uC for 1 hour in vertical orientation and rehydrated in xylene and
graded alcohol series. Thereafter, antigen retrieval conditions were
optimized and was carried out in 0.01 M citrate buffer, pH 6.0 for
3 minutes at 115uC, using a TTmega oven (Milestone Inc. Shelton,
CT). Endogenous peroxidase activity was blocked by incubating
sections in methanol containing 0.3% hydrogen peroxide for
20 minutes. After blocking the non-specific binding with normal
horse or goat serum, the sections were incubated with a-E p - I C D
rabbit monoclonal antibody 1144 (dilution 1:200) for 30 minutes and
biotinylated goat anti-rabbit secondary antibody for 30 minutes or
incubated with MOC-31 (dilution 1:200) for 30 minutes with the
corresponding biotinylated secondary antibody (horse anti-mouse or
goat anti-rabbit) (Vector Laboratories, Burlington, Ontario, Canada)
for 30 minutes. The sections were finally incubated with VECTAS-
TAIN Elite ABC Reagent (Vector Laboratories) and diaminobenze-
d i n ew a su s e da st h ec h r o m o g e n .
Evaluation of immunohistochemical staining
The TMA images were acquired using the Visiopharm
Integrator System (Visiopharm, Horsholm, Denmark). Ep-ICD
and EpEx immunopositive staining was evaluated in five areas of
the acquired images of the tissue sections and the average of these
five scores was calculated. Sections were scored as positive if
epithelial cells showed immunopositivity in the plasma membrane,
cytoplasm, and/or nucleus when observed by two evaluators who
were blinded to the clinical histopathology and diagnosis. These
sections were scored on the basis of percentage positivity as
follows: 0, ,10% cells; 1, 10–30% cells; 2, 30–50% cells; 3, 50–
70% cells; and 4, .70% cells showed immunoreactivity as
described earlier [28]. Sections were also scored semi-quantita-
tively on the basis of intensity as follows: 0, none; 1, mild; 2,
moderate; and 3, intense. Finally, a total score (ranging from 0 to
7) was obtained by adding the scores of percentage positivity and
intensity for each cancer and normal tissue section. The
immunohistochemical data were subjected to statistical analysis
as described previously [29].
Statistical analysis
The IHC data were subjected to statistical analysis using SPSS
17.0 software (SPSS, Chicago, IL) and Graphpad Prism 5
(GraphPad Software, La Jolla, CA). Scatter plots were used to
determine the distribution of total score for membrane, nuclear,
and cytoplasmic Ep-ICD expression in normal and cancerous
tissues. Receiver operating characteristic (ROC) curve analyses
were performed to calculate the sensitivity, specificity and area
under the curve (AUC) values in each cancer type for nuclear and
cytoplasmic Ep-ICD. Based on the optimal sensitivity and
specificity, an IHC score cut-off value of $4 was defined as
immunopositive uniformly for all the cancer types analyzed for
statistical examination.
Immunofluorescence analysis of Ep-ICD and EpEx
localization in CX-1 colon cancer cell line
CX-1 colon cancer cells were grown on glass slides up to 60%
confluence and then incubated with either a-Ep-ICD rabbit
monoclonal antibody 1144 (1:100 dilution) or mouse monoclonal
antibody MOC-31 (1:100). For Ep-ICD, the secondary antibody
used was a tetramethyl rhodamine isothiocyanate (TRITC)-
labeled goat anti-rabbit antibody (Sigma-Aldrich, 1:200 dilution).
For EpEx, the secondary antibody used was a fluorescein
isothiocyanate (FITC)-labeled goat anti-mouse antibody (Sigma-
Aldrich, St. Louis, MO, 1:200 dilution). Slides were viewed using
an Olympus Upright fluorescence microscope (BX61) and images
were analyzed using Volocity software (PerkinElmer, Waltham,
MA).
Table 1. Summary of Immunohistochemical Analysis of Ep-ICD in Normal and Epithelial Cancers.
Tissue Type
Cancer or
Normal
Number
Tissues (n)
Nuclear
Positive (n)
Nuclear
Positivity (%)
Cytoplasmic
Positive (n)
Cytoplasmic
Positivity (%)
Prostate Cancer 49 40 82 40 82
Normal 922 21 1 1
BPH 21 0 0 1 5
Breast Cancer 38 31 82 32 84
Normal 25 0 0 0 0
Head and Neck Cancer 57 37 65 42 74
Normal 20 1 5 1 5
Esophagus Cancer 46 17 37 32 70
Normal 20 2 10 6 30
Lung Cancer 59 47 80 56 95
Colon Cancer 59 49 83 46 78
Ovary Cancer 10 10 100 10 100
Pancreas Cancer 10 3 30 2 20
Liver Cancer 991 0 0 8 8 9
Bladder Cancer 10 9 90 9 90
doi:10.1371/journal.pone.0014130.t001
Ep-ICD in Epithelial Cancers
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Immunohistochemical analysis of Ep-ICD expression in
human epithelial cancers
The known clinical parameters, histopathology, and Ep-ICD
IHC scores for each cancer type are provided in the Supplemen-
tary Tables S1, S2, S3, S4, S5, S6, S7, S8, S9, S10. Among the
cancer types that were compared to the normal tissues (Table 1),
breast cancers exhibited 82% nuclear Ep-ICD positivity (31 of 38
tissues) and 84% cytoplasmic Ep-ICD positivity (32 of 38 tissues).
Based on an IHC cut-off score of 4, none of the 25 normal breast
tissues analyzed were considered positive for nuclear Ep-ICD;
56% (14 of 25 tissues) showed no detectable nuclear staining in
breast lobular cells or ductal cells, while the remaining 11 cases
showed low IHC scores. Prostate cancers exhibited 82% nuclear
positivity (40 of 49 tissues) and 82% cytoplasmic positivity (40 of 49
tissues). Nuclear Ep-ICD was positive in 2 of 9 normal prostate
tissues, and cytoplasmic positivity was observed in 1 of 9 tissues.
Among the 21 BPH tissues analyzed, cytoplasmic positivity was
observed in 1 of 21 tissues; none of the tissues were nuclear Ep-
ICD positive based on a cutoff score of 4. In HNSCCs, Ep-ICD
nuclear positivity was 65% (37 of 57 tissues) and cytoplasmic
positivity was 74% (42 of 57 tissues). ESCC nuclear positivity was
37% (17 of 46 tissues) and cytoplasmic positivity was 70% (32 of 37
tissues). Nuclear and cytoplasmic Ep-ICD was each observed to be
positive in only 1 of 20 normal tissues in head and neck cancer.
For ESCC, nuclear positivity was observed in 2 of 20 normal
tissues and cytoplasmic positivity was observed in 6 of 20 normal
tissues. All remaining epithelial cancers displayed nuclear and
cytoplasmic accumulation of Ep-ICD (Table 1). Notably, although
the use of a cutoff of $4 to determine positivity led to reduced
nuclear and cytoplasmic positivity in pancreatic cancers, an
examination of the scoring revealed that a cutoff of 3.5 would have
identified 7 of 10 cases of nuclear Ep-ICD accumulation and 5 of
10 cases of cytoplasmic Ep-ICD accumulation (See Supplementary
Table S8).
The representative photomicrographs shown in Figure 1
demonstrate Ep-ICD immunostaining in normal and cancer
tissues. Panel A shows predominant membrane localization of
Ep-ICD and no nuclear staining in the normal breast tissue (I),
while the cancer tissue shows nuclear and cytoplasmic Ep-ICD
accumulation (II). Panel B (Ia) depicts low level of membrane Ep-
ICD in the epithelial cells and the basal cells show slight nuclear
staining in the normal prostate tissue and in benign prostate
hyperplasia (Ib). The prostate cancer tissue shows intense
cytoplasmic and increased nuclear staining (panel B, II). In
endothelial cells, strong Ep-ICD staining was consistently
observed. In adipocytes, staining ranged from absent to mild in
some cells. Lymphocytes stained strongly in tumor tissues, whereas
none was observed in normal tissues. Smooth muscle staining was
absent or weak in all cases. No detectable Ep-ICD staining was
observed in the normal esophageal tissue (panel C, I), while the
ESCC showed intense nuclear and cytoplasmic immunostaining
(panel C, II). The head and neck normal mucosa showed
faint membrane Ep-ICD (panel D, I), while intense nuclear
and cytoplasmic immunostaining was observed in HNSCC
(panel D, II).
Increased nuclear and cytoplasmic immunoreactivity and
reduced or absence of membrane staining of Ep-ICD was
observed in cancers of the bladder (Figure 2, panel A), lung (B),
liver (C), ovary (D), colon (E), and pancreas (F). Notably,
membrane Ep-ICD staining was observed in some cases of each
epithelial cancer analyzed. Representative photomicrographs of
prostate cancer and colon cancer depicting heterogeneous Ep-ICD
staining are shown in Figure 3 A, B. Some areas of the tissue
section showed predominant membrane and weak cytoplasmic but
no nuclear localization of Ep-ICD (Figure 3A, B - left square),
while the other areas of the same tissue section showed nuclear
and cytoplasmic accumulation of Ep-ICD with absence of
membranous Ep-ICD expression (Figure 3A, B - right square).
The negative and positive control photomicrographs are shown in
Figure 4.
Scatter Plot Analysis
The scatter plots in Figure 5A and 5B show the distribution of
nuclear and cytoplasmic Ep-ICD immunostaining scores in all the
epithelial cancer types analyzed. Nuclear Ep-ICD was observed in
39 of the 57 HNSCC tissues and in 18 of the 46 ESCC tissues.
Thirty seven of these 39 HNSCC tissues examined and 17 of the
18 ESCC tissues showed IHC score $4. Cytoplasmic Ep-ICD
staining was detected in 42 of the 57 (74%) HNSCC tissues
examined and 32 of the 46 (70%) ESCC tissues. Breast cancer,
prostate cancer, and positively-staining HNSCCs and ESCCs all
exhibited notable elevations of both nuclear and cytoplasmic Ep-
ICD compared to the normal tissues and prostate benign
hyperplastic tissues analyzed. Lung, colon, liver, bladder, ovarian,
and pancreatic cancer types each demonstrated prominent
expression of nuclear and cytoplasmic Ep-ICD. The scatter plots
in Figure 5C show the distribution of membrane Ep-ICD scores in
all the epithelial cancer types analyzed.
Immunohistochemical analysis of EpEx expression in
human epithelial cancers
Similar IHC analysis of EpEx expression in these human
epithelial cancers was also carried out using MOC31, a specific
antibody against the extracellular domain of EpCAM (EpEx) in all
the ten epithelial cancers (Figure 6 and 7). Representative
photomicrographs in Figure 6, panel I show low level of
membrane EpEx expression in normal breast (A) and prostate
(B, Ia), BPH (B, Ib), and normal esophagus (C) and head and neck
(D) tissues. The corresponding cancer tissues depicting increased
level of EpEx in the membrane are shown in Figure 6, panel II (A-
breast; B-prostate; C- esophagus; and D- head and neck). In
contrast, many of the cancer tissues of each cancer type showed
absence of membrane EpEx; representative photomicrographs are
shown in panel III (A–D). Figure 7, panel I shows intense
membrane EpEx in colon cancer (A), liver (B), bladder (C), lung
(D), ovary (E) and pancreatic (F) cancer. Figure 7 panel II (A–F)
shows reduced or absence of membrane EpEx in a subset of each
Figure 1. Immunohistochemical analysis of Ep-ICD expression in epithelial cancers and normal tissues. The representative
photomicrographs depict Ep-ICD immunostaining in normal and cancer tissues. Panel A shows predominant membrane localization of Ep-ICD and no
nuclear staining in the normal breast tissue (I), while the cancer tissue shows nuclear and cytoplasmic Ep-ICD accumulation (II). Panel B shows low
level of membrane Ep-ICD in the epithelial cells and the basal cells show some nuclear staining in the normal prostate tissue (Ia) and in benign
prostate hyperplasia (B, Ib), while the cancer tissue shows intense cytoplasmic and nuclear staining (II). Panel C shows no detectable Ep-ICD staining
in the normal esophageal tissue (I), while the ESCC shows intense nuclear and cytoplasmic immunostaining (II). Panel D depicts head and neck normal
mucosa showing faint membrane Ep-ICD (I), while the HNSCC shows intense nuclear and cytoplasmic immunostaining (II). Original magnification
6400.
doi:10.1371/journal.pone.0014130.g001
Ep-ICD in Epithelial Cancers
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shown in Supplementary Figure S1.
Analysis of Ep-ICD and EpEx immunofluorescence in CX-1
colon cancer cell line
In CX-1, an aggressive colon cancer cell line, EpEx and Ep-
ICD were both detected in the plasma membrane (Figure 8).
Intense membrane expression was observed at cell-cell junctions
with both EpEx and Ep-ICD domain specific antibodies (Figure 8
- A, D, F, and G). In addition, accumulation of Ep-ICD was
observed in the cytoplasm and nuclei of cancer cells, but no EpEx
accumulation was found in the nuclei (Figure 8 - C, E, G). The
quantitative fluorescence signal scan of EpEx and Ep-ICD clearly
supports these observations (Figure 8H).
ROC Curve Analysis
ROC curves were generated for nuclear and cytoplasmic Ep-
ICD in HNSCC, ESCC, prostate, and breast cancers (Figure 9)
and their results are summarized in Table 2. Based on this
analysis, a cutoff of $4 was used to determine nuclear and
Figure 2. Immunohistochemical analysis of Ep-ICD expression in epithelial cancers. Increased nuclear and cytoplasmic immunoreactivity
and reduced or absence of membrane staining of Ep-ICD was observed in cancers of the bladder (Panel A), lung (Panel B), liver (Panel C), ovary (Panel
D), colon (Panel E), and pancreas (Panel F). Original magnification 6400.
doi:10.1371/journal.pone.0014130.g002
Ep-ICD in Epithelial Cancers
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accumulation distinguished prostate cancers and breast cancers
from normal tissues with 82% sensitivity and with a specificity of
100% for breast and 78% for prostate. In HNSCCs, nuclear Ep-
ICD was able to distinguish cancers from normal tissues with 65%
sensitivity and 95% specificity, while in ESCCs, nuclear Ep-ICD
showed 37% sensitivity and 90% specificity. The AUC values were
found to be 0.905 for breast cancer, 0.867 for prostate cancer,
0.822 for HNSCC, and 0.630 for ESCC. Cytoplasmic Ep-ICD
expression in breast and prostate cancer had a sensitivity of 82%
and 84% respectively, with a specificity of 100% for breast and
89% for prostate. In HNSCC, cytoplasmic Ep-ICD expression
had a sensitivity of 74% and a specificity of 95%, while
cytoplasmic Ep-ICD had sensitivity and specificity of 70% each
in ESCCs. The AUC values for cytoplasmic Ep-ICD were 0.928
in breast cancer, 0.880 in prostate cancer, 0.864 in HNSCC, and
0.758 in ESCC.
Discussion
The current study highlights the frequent occurrence of nuclear
and cytoplasmic accumulation of Ep-ICD in ten epithelial cancer
types. The normal epithelia of the breast, prostate and esophageal
tissues analyzed showed distinct membrane Ep-ICD localization.
Importantly, reduced or absence of membranous Ep-ICD was
observed in cancers of breast, prostate, head and neck and
esophagus, paralleled by marked Ep-ICD accumulation in the
nucleus and cytoplasm of the respective tumor cells. However, a
subset of tumors of each of these ten cancer types showed high Ep-
ICD membrane expression that correlated with high EpEx
expression on the membrane detected using an Ep-CAM external
domain (EpEx) specific antibody (MOC31), suggesting increased
expression of the full length protein as detected by Ep-ICD and
EpEx specific antibodies. Notably, immunohistochemical analysis
of epithelial cancers using MOC31 showed increased EpEx
membrane expression in comparison with the normal tissues in
some tumors, while the others showed reduced or absence of
membrane EpEx, supporting our observations with Ep-ICD
domain specific antibodies. It is worthwhile to point out that
cancers showing reduced or absence of membrane EpEx or Ep-
ICD had markedly increased Ep-ICD in the cytoplasm and nuclei
of such tumor cells. Notably, EpEx was not detected in any of the
nuclei of tumor cells in any of the cancers analyzed. Taken
together, these observations favor increased expression and
increased shedding of EpEx by tumor cells in a subset of all
epithelial tumors studied. The dual labeling immunofluorescence
studies in an aggressive colon cancer cell line also clearly
demonstrated localization of EpEx and Ep-ICD on the mem-
brane, especially at the cell- cell contacts, with increased
cytoplasmic and nuclear Ep-ICD expression. These observations
favor increased expression and shedding of EpEx in cancer cells.
Furthermore, we found increases in nuclear and cytoplasmic Ep-
Figure 3. Immunohistochemical analysis of Ep-ICD expression in prostate and colon cancers. Membrane, cytoplasmic, and nuclear Ep-
ICD expression in prostate cancer (A) and colon cancer (B). Some areas of the tissue section show predominant membrane and weak cytoplasmic but
no nuclear localization of Ep-ICD (A, B - left square), while the other areas of the same tissue section show nuclear and cytoplasmic accumulation of
Ep-ICD with absence of membranous Ep-ICD expression (A, B - right square). Original magnification 6400.
doi:10.1371/journal.pone.0014130.g003
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PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e14130Figure 4. Ep-ICD immunohistochemical analysis in epithelial cancers control tissues. The negative and positive control photomicrographs
are shown. Ep-ICD negative controls for HNSCC (A), prostate cancer (B), colon cancer (C), breast cancer (D), ESCC (E), and normal esophagus (F); panels
G and H are positive controls for Ep-ICD staining. Original magnification 6400.
doi:10.1371/journal.pone.0014130.g004
Ep-ICD in Epithelial Cancers
PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e14130Figure 5. Scatter plot analysis of Ep-ICD membrane, cytoplasmic, and nuclear expression. Scatter plots showing distribution of total
immunostaining scores determined by IHC of tissue sections of cancers of the breast (n=38), prostate (n=49), lung (n=59), ovary (n=10), colon
(n=59), bladder (n=10), liver (n=9), positively-staining HNSCCs (n=39) and ESCCs (n=19), and normal breast (n=25), prostate (n=9) and BPH
(n=21), normal esophageal (n=20), and head and neck (n=20) tissues. The vertical axis gives the total IHC score as described in the Methods. A
cutoff of $4 was used to determine positivity. N, normal; Ca, cancer. A. Increased nuclear accumulation of Ep-ICD was observed in most of the
epithelial cancers analyzed. B. Increased cytoplasmic accumulation of Ep-ICD was observed in almost all epithelial cancers analyzed. C. Membrane
localization of Ep-ICD varied in the different cancer and normal tissue types examined.
doi:10.1371/journal.pone.0014130.g005
Ep-ICD in Epithelial Cancers
PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e14130Figure 6. Immunohistochemical analysis of EpEx expression in epithelial cancers. The photomicrographs depict MOC31 stained
membrane EpEx in epithelial cancers. The panel I shows low level of membrane EpEx expression in normal breast (A) and prostate (B, Ia), BPH (B, Ib),
and normal esophagus (C) and head and neck (D) tissues. The corresponding cancer tissues depicting increased level of EpEx in the membrane are
shown in panel II (A–D). In contrast many of the cancer tissues of each cancer type showed absence of membrane EpEx (panel III, A–D). Original
magnification 6400.
doi:10.1371/journal.pone.0014130.g006
Ep-ICD in Epithelial Cancers
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cancers as well as reduced or absence of membrane EpEx in these
cancers. However, some tumors of each of the ten cancer type
analyzed showed intense membrane EpEx expression. It is
important to note that our observations are in accordance with
the summary of EpCAM data in the Human Protein Atlas
database (http://www.proteinatlas.org/) using EpEx-specific
antibodies that reported variable expression of EpCAM in
different human cancers. The novelty of our study is the use of
Ep-ICD specific antibodies for IHC analysis of Ep-ICD
Figure 7. Immunohistochemical analysis of EpEx expression in epithelial cancers. Membrane EpEx expression was observed in all the
epithelial cancers. Panel I shows intense membrane EpEx in colon cancer (A), liver (B), bladder (C), lung (D), ovarian (E) and pancreatic (F) cancer. The
panels II A–F show reduced or absence of membrane EpEx in a subset of each of these epithelial cancers. Original magnification 6400.
doi:10.1371/journal.pone.0014130.g007
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nuclear and cytoplasmic Ep-ICD expression with the paralleled
reduction or absence of membranous Ep-ICD in subsets of each
of these cancer types.
Except for a previous report on Ep-ICD in colon cancer [24]
and our study on thyroid cancer [28], this study represents the first
report on Ep-ICD occurrence in cancers of breast, prostate, head
and neck, esophagus, ovary, lung, urinary bladder, pancreas and
liver. The diagnostic utility of nuclear and cytoplasmic Ep-ICD
expression was validated by the vast difference in their observed
expression levels between normal tissue and the breast and
prostate cancers. Nuclear Ep-ICD expression was able to
distinguish normal tissue from breast and prostate cancers with
AUC values of 0.905 and 0.867 respectively and with 82%
sensitivity and 100% specificity for breast cancers and 82%
sensitivity and 78% specificity for prostate cancers. For the head
and neck cancers nuclear Ep-ICD had an AUC value of 0.822,
with 65% sensitivity and 95% specificity and cytoplasmic Ep-ICD
also showed similar diagnostic performance. The esophageal
cancers showed an AUC value of 0.758, with 70% sensitivity and
70% specificity for cytoplasmic Ep-ICD, though lower frequency
of nuclear positivity was observed in these cancers. The high
sensitivity, specificity, and AUC value of nuclear and cytoplasmic
Ep-ICD expression in prostate, breast and head and neck cancers
underscore its diagnostic utility in these malignancies. Further-
more, high frequencies of nuclear and cytoplasmic Ep-ICD were
observed in lung and colon cancers, though the non-availability of
normal tissues precluded the determination of ROC analysis for
these cancers. High nuclear and cytoplasmic Ep-ICD immuno-
positivity was observed in cancers of the liver, bladder and ovary;
the small number of cases analyzed nevertheless establishes the
occurrence of Ep-ICD in these cancers, although further studies
using larger cohorts are needed to determine the diagnostic
significance of Ep-ICD versus EpEx subcellular accumulation in
these epithelial cancers.
Quantitative real-time-PCR analyses of EpCAM expression in
tumors and in circulating tumor cells from patients with many of
these epithelial cancers reported increased levels of EpCAM
transcripts that prospectively demonstrated prognostic signifi-
cance for breast, colorectal and prostate cancer patients
with advanced disease [30,31,32,33,34,35]. A recent study by
Punnoose et al., [34] reported EpCAM-based circulating tumor
cell count to be higher in ER+ breast cancer patients in
comparison to HER2+ and triple negative patients. The low
EpCAM expression in HER2+ and triple negative breast cancers
was attributed to a more mesenchymal phenotype. Another
report on EpCAM expression in surgical specimens from
esophageal cancer patients (n=138), using real-time RT-PCR,
IHC and ELISA showed that the mean expression level of
EpCAM mRNA in tumor tissues was significantly higher than
that in corresponding normal tissues (P,0.0001) [36]. The
survival rates of patients with high EpCAM expression in tumors
and in the peripheral vein were significantly higher than those for
patients having low EpCAM expression. However, further
studies will be needed to determine if low EpCAM expression
in these tumors can be attributed to its regulated intramembrane
proteolysis. The prognostic relevance of Ep-ICD versus EpEx
subcellular expression in epithelial cancers remains to be
examined in future studies. Notably, our earlier report in thyroid
cancers demonstrated a strong association between nuclear
accumulation of Ep-ICD and a reduced membranous EpEx
localization as well as shortened overall survival, suggesting the
potential application of the relative subcellular expression of Ep-
ICD versus EpEx as prognostic markers for aggressive thyroid
cancers. Taken together with the findings of the current study,
our observations strongly support that the accumulation of
nuclear and /or cytoplasmic Ep-ICD could favour its clinical
application as a putative prognostic marker in several epithelial
c a n c e r ss u r v e y e di nt h i sr e p o r t .I ti st h e r e f o r ei m p o r t a n t
to examine in future studies, the potential of nuclear and
Figure 8. Fluorescence immunostaining in CX-1 cells with anti-EpEx (MOC31) and anti-Ep-ICD antibodies. Secondary antibodies are
FITC-anti-mouse (green) and TRITC-anti-rabbit (red). A) EpEx; B) Ep-ICD; C) DAPI; D) EpEx and DAPI (A&C merged); E) Ep-ICD and DAPI (B & C merged);
F) EpEx and Ep-ICD (A & B merged); G) EpEx, Ep-ICD, and DAPI (A, B, C merged); I) Measurement of the density of three colors across the line in the
cells in H.
doi:10.1371/journal.pone.0014130.g008
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prognostic indicator(s) of aggressive subtypes of many other
epithelial cancers anticipated to have shortened life expectancy
and the need for more aggressive therapies. Such studies
conducted on large cohorts will be essential in understanding
the clinical significance of nuclear and cytoplasmic Ep-ICD
accumulation and thereby lead to the translation of such findings
to novel diagnostic and treatment strategies.
Figure 9. ROC curves of nuclear and cytoplasmic Ep-ICD in prostate cancer, breast cancer, HNSCC, and ESCC. ROC curves describing
the relationship between sensitivities and 1-specificities of nuclear and cytoplasmic Ep-ICD expression in these epithelial cancers. The vertical axis of
each curve indicates sensitivity and the horizontal axis indicates the 1-specificity. The sensitivity, specificity, and AUC values for the cancers are
summarized in Table 2.
doi:10.1371/journal.pone.0014130.g009
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on monoclonal antibodies to EpEx including the humanized
antibodies that are in phase III trials [37]. Our current findings in
a large spectrum of epithelial cancers suggest that absence of
membranous EpEx and the increase in nuclear and cytoplasmic
accumulation of Ep-ICD may explain the limited efficacy of EpEx-
directed targeted therapies in some of these epithelial cancers,
including breast cancer [22]. Ep-ICD directed targeted therapies
are likely to be effective in the management of cancers showing
enhanced nuclear and cytoplasmic accumulation of Ep-ICD. The
future application of targeted immunotherapy may thereby
require improved individualized immunodiagnostic selection of
patients based on their relative expression of Ep-ICD versus EpEx
in the tumors of each affected patient. This therapeutic goal may
be achieved by developing robust high throughput assays on
clinical tumor tissue samples for these two EpCAM components to
serve as a guide to target monoclonal antibody therapy. This
strategy offers the hope that the results for many epithelial cancers
can be enhanced by determining the appropriate EpCAM target.
Conclusions
In conclusion, we provide new evidence of increased nuclear
and cytoplasmic Ep-ICD accumulation and a variable increase or
absence of membrane EpEx expression in a wide variety of
epithelial cancers. The high frequency of nuclear and cytoplasmic
Ep-ICD accumulation observed in most epithelial cancers studied
to-date strongly suggests that Ep-ICD may play an important role
in epithelial-derived cancers. The high AUC value of Ep-ICD and
its ability to distinguish cancers from normal tissues with high
sensitivity and specificity, suggests it may serve as a putative
biomarker for increased oncogenesis. Future diagnostic, prognostic
and targeted therapies may be improved by more refined selection
of patients based on Ep-ICD versus EpEx expression in tumors.
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Figure S1 EpEx immunohistochemical analysis in epithelial
cancers control tissues. The negative control photomicrographs are
shown. HNSCC (A), prostate cancer (B), colon cancer (C), breast
cancer (D), ESCC (E) and normal esophagus (F); panels G and H are
positive controls for EpEx staining. Original magnification 6400.
Found at: doi:10.1371/journal.pone.0014130.s001 (6.53 MB TIF)
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Table S2 Ep-ICD Accumulation and Clinical Parameters of
Lung Cancer Patients. Abbreviations: AC: adenocarcinoma; BAC:
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differentiated; NM=non-mucinous; PD: poorly-differentiated;
WD=well-differentiated.
Found at: doi:10.1371/journal.pone.0014130.s003 (0.11 MB
PDF)
Table S3 Ep-ICD Accumulation and Clinical Parameters of
Colon Cancer Patients. Abbreviations: AC: adenocarcinoma; MC:
mucinous carcinoma; MD: moderately-differentiated; PD: poorly-
differentiated; WD=well-differentiated.
Found at: doi:10.1371/journal.pone.0014130.s004 (0.08 MB
PDF)
Table S4 Ep-ICD Accumulation and Clinical Parameters of Breast
Cancer Patients. Abbreviations: IDC: infiltrating duct carcinoma.
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Table S5 Ep-ICD Accumulation and Clinical Parameters of
Liver Cancer Patients.
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Table S6 Ep-ICD Accumulation and Clinical Parameters of
Bladder Cancer Patients. Abbreviations: TCC: transitional cell
carcinoma.
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PDF)
Table S7 Ep-ICD Accumulation and Clinical Parameters of
Ovarian Cancer Patients. Abbreviations: MAC: mucinous adeno-
carcinoma; MD: moderately differentiated; PD: poorly differen-
tiated; SAC: serous adenocarcinoma.
Found at: doi:10.1371/journal.pone.0014130.s008 (0.02 MB
PDF)
Table S8 Ep-ICD Accumulation and Clinical Parameters of
Pancreatic Cancer Patients. Abbreviations: MDDAC: moderately
differentiated ductal adenocarcinoma; PDDAC: poorly differenti-
ated ductal adenocarcinoma.
Found at: doi:10.1371/journal.pone.0014130.s009 (0.02 MB
PDF)
Table S9 Ep-ICD Accumulation and Clinical Parameters of
HNSCC Patients. Abbreviations: MD: moderately differentiated;
Table 2. Biomarker Analysis of Nuclear and Cytoplasmic Ep-ICD Expression in Epithelial Cancers.
Ep-ICD Nuclear IHC Scores AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%) Asymptotic Sig.
Prostate Cancer vs. Normal 0.867 82 78 95 44 0.001
Breast Cancer vs. Normal 0.905 82 100 100 78 0.000
HNSCC vs. Normal 0.822 65 95 97 49 0.000
ESCC vs. Normal 0.630 37 90 90 38 0.001
Ep-ICD Cytoplasmic IHC Scores AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%) Asymptotic Sig.
Prostate Cancer vs. Normal 0.880 82 89 98 47 0.000
Breast Cancer vs. Normal 0.928 84 100 100 81 0.000
HNSCC vs. Normal 0.864 74 95 98 56 0.000
ESCC vs. Normal 0.758 70 70 84 50 0.001
doi:10.1371/journal.pone.0014130.t002
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moderately differentiated; PD: poorly differentiated; SCC: squa-
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